¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hyper-IgM Immunodeficiency Syndrome, Type 1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • empty nest syndrome
    ºóµÕÁöÁõÈıº
  • empty sella syndrome
    ºó¾ÈÀåÁõÈıº
  • entrapment syndrome
    Æ÷ÂøÁõÈıº
  • eosinophilia-myalgia syndrome
    È£»ê±¸Áõ°¡±Ù(À°)ÅëÁõÁõÈıº
  • epidermal nevus syndrome
    Ç¥ÇǸð¹ÝÁõÈıº
  • ectopic ACTH syndrome
    µý°÷ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸óÁõÈıº, À̼ҼººÎ½ÅÇÇÁúÀÚ±ØÈ£¸£¸óÁõÈıº
  • facet syndrome
    ÈİüÀýÁõÈıº
  • Felty¡¯s syndrome
    ÆçƼÁõÈıº
  • fertile eunuch syndrome
    °¡ÀÓ°íÀÚÁõÈıº
  • fetal alcohol syndrome
    žƾËÄÚ¿ÃÁõÈıº
  • fetal distress syndrome
    žưï¶õÁõÈıº
  • fetal hydantoin syndrome
    žÆÈ÷´ÜÅäÀÎÁõÈıº
  • fibromyalgia syndrome
    ¼¶À¯±ÙÅëÁõÈıº
  • Fisher syndrome
    ÇǼÅÁõÈıº
  • fish-odor syndrome
    ¹°°í±âÇâÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • deficit syndrome
    °áÇÌÁõÈıº
  • delayed sleep phase syndrome
    ¼ö¸éÀ§»óÁö¿¬ÁõÈıº
  • depersonalization-derealization syndrome
    ÀÌÀκñÇö½Ç°¨ÁõÈıº
  • discontinuation syndrome
    ºÒ¿¬¼ÓÁõÈıº
  • dissociation syndrome
    ÇØ¸®ÁõÈıº
  • dry eye syndrome
    ´«¸¶¸§ÁõÈıº, ¸¶¸¥´«ÁõÈıº
  • dumping syndrome
    ´ýÇÎÁõÈıº
  • dyskinetic syndrome
    ÀÌ»ó¿îµ¿ÁõÈıº
  • electrolyte deficiency syndrome
    ÀüÇØÁú°áÇÌÁõÈıº
  • empty nest syndrome
    ºóµÕÁöÁõÈıº
  • empty-sella syndrome
    ºó¾ÈÀåÁõÈıº
  • entrapment syndrome
    Æ÷ÂøÁõÈıº, ÁËÀÓÁõÈıº, µ£ÁõÈıº
  • eosinophilia myalgia syndrome
    È£»ê±¸Áõ°¡±ÙÀ°ÅëÁõÈıº
  • epidermal nevus syndrome
    Ç¥ÇǸð¹ÝÁõÈıº
  • exfoliation syndrome
    ¼öÁ¤Ã¼ºñ´ÃÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • Chilaiditis syndrome
    ų¶óÀ̵ðƼÁõÈıº.
  • Chronic fatigue syndrome
    ¸¸¼ºÇÇ·Î ÁõÈıº
  • Churg-Strauss syndrome
    Ãʱ×-½ºÅä¶ó¿ì½º ÁõÈıº
  • Cockayne syndrome
    ÄÚÄÉÀÎ ÁõÈıº(~ ñøý¦ÏØ)
  • Cockaynes syndrome
    ÄÚÄÉÀÎ ÁõÈıº
  • Coffin-Lowry syndrome
    ÄÚÇÉ-·Î¸® ÁõÈıº
  • Coffin-Siris syndrome
    ÄÚÇÉ-½Ã¸®½º ÁõÈıº
  • Cogan-Reese syndrome
    ÄÚ°£-¸®½ºÁõÈıº
  • Conn syndrome
    ÄÜÁõÈıº
  • Conns syndrome
    ÄÜÁõÈıº.
  • Conradi syndrome => chondrodysplasia calcificans congenita
    ¼±Ãµ¼º Ä®½·È­ ¿¬°ñ ÀÌÇü¼º
  • Conradi-Hunermann syndrome => chondrodysplasia punctata, autosomal dom
    »ó¿°»öü ¿ì¼ºÇü Á¡»ó¿¬°ñ ÀÌÇü¼º
  • Costens syndrome
    ÄÚ½ºÅÙ ÁõÈıº
  • Cotards syndrome
    ÄÚŸ¸£ÁõÈıº.
  • Cri du chat syndrome ºÒ
    ¹¦¼ºÁõÈıº.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • linear array type
    ¼±Çü ¹è¿­½Ä (àÊû¡ ÛÕÖªãÒ)
  • linear type constitution
    ¼±Ã¼Çü.
  • lymphatic type
    ¸²ÇÁÇü(¡­úþ).
  • mating type
    ±³¹èÇü
  • men type
    MEN Çü(¡­ û¡)
  • meningeal type
    ¼ö¸·Çü(âÐØ¯úþ).
  • metaphyseal dysostosis dominant type
    °ñ °£´Ü¼º À̰ñÁõ ¿ì¼ºÇü(ÍéÊÏÓ®àõì¶ÍéñøéÐàõúþ).
  • metaplastic bone (type)
    È­»ý°ñ(Çü)(ûùßæÍéû¡).
  • mixed type of artery
    È¥ÇÕÇüµ¿¸Æ
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü(¡­û¡).
  • monocytic type
    ´ÜÇÙ±¸Çü(Ó¤ú·Ï¹û¡)
  • monocytic type
    ´ÜÇÙ±¸Çü(?Ì´).
  • muscular type of artery
    ±ÙÀ°Çüµ¿¸Æ
  • muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
HIV human immunodeficiency virus
HIV Ag human immunodeficiency virus antigen
HIVAN human immunodeficiency virus-associated nephropathy
HIV-G human immunodeficiency virus-associated gingivitis
ID identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
WS1 Waardenburg syndrome Type I
"syndrome X" syndrome
11 beta-HSD-1 11 beta-Hydroxysteroid dehydrogenase type 1
11 beta-HSD2 11 beta-Hydroxysteroid dehydrogenase type 2
5-HT3 5-hydroxytryptamine type 3
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Bechet syndrome
    º£Ã¼Æ® ÁõÈıº
    º£Ã¼Æ® ÁõÈıºÀº ¹Ýº¹µÇ´Â ±¸°­ ¹× ¼º±âÀÇ ±Ë¾ç°ú ´« ¹× ÇǺΠµîÀ» ħ¹üÇÏ´Â ¿©·¯ ±â°ü¿¡ ¿À´Â ÁúȯÀÌ´Ù. ¾ÆÁ÷±îÁö È®½ÇÇÑ ¿øÀÎÀº ¸ð¸£Áö¸¸ Ç÷°ü¿°ÀÌ ÁÖµÈ º´¸® ¼Ò°ßÀ̰í ÀÚ°¡ Ç×ü°¡ 50%¿¡¼­ ÃâÇöÇÏ´Â °ÍÀ¸·Î º¸¾Æ¼­ ÀÚ°¡¸é¿ª ÁúȯÀÇ Çϳª¶ó°í »ý°¢Çϰí ÀÖ´Ù. Áõ»óÀÇ Á¤µµ´Â ½Ã°£ÀÌ °¡¸é ´úÇØÁö°í ½ÉÇÑ ÇÕº´ÁõÀÌ ¾ø´Â ÇÑ ¼ö¸í°ú´Â °ü°è°¡ ¾ø´Ù. ±×·¯³ª Ä¡·á´Â Ưº°ÇÑ °ÍÀÌ ¾ø°í ´ëÁõÀûÀÌ°í °æÇèÀûÀÎ Ä¡·á¸¦ ÇϰԵǾî Áõ»ó¿¡ µû¶ó¼­
  • Behcet's syndrome
    º£Ã¼Æ® ÁõÈıº, Behcet ÁõÈıº
    ±¸°­, ´«, ¼º±âÀÇ º´¼Ò°¡ Ư¡ÀΠƯ¹ß¼º Áúȯ. ´«¿¡¼­ º¼ ¼ö ÀÖ´Â ¼Ò°ßÀº Æ÷µµ¸·¿°, ¸Á¸·¿° ¹× °á¸·¿°À̰í, ¼º±â¿¡ ³ªÅ¸³ª´Â ¼Ò°ßÀº ´ë°³°¡ ÇÇºÎ¿Í Á¡¸·ÀÇ ±Ë¾çÀ̸ç, ±¸°­¿¡ ³ªÅ¸³ª´Â ¼Ò°ßÀº À¯»ç ¾ÆÇÁŸ¼º ±Ë¾çÀÌ´Ù. Áø´ÜÀº ÀÓ»ó ¼Ò°ß¿¡ ±Ù°ÅÇÑ´Ù. Ä¡·á¿¡´Â Àü½Å¼º ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å Åõ¿©¸¦ ÀÌ¿ë. À¯ÀüÀû ¿ä¼Ò°¡ ÀÖ´Ù°í º¸°íµÇ°í ÀÖ´Ù.
  • big heart syndrome
    °Å½É ÁõÈıº
  • black cardiac syndrome
    Èæ½ÉÀå ÁõÈıº
  • Boerhaave syndrome
    ºÆ¸£ÇϺ£ ÁõÈıº
    ±¸Åä·Î ÀÎÇØ ½ÄµµÀÇ ÀÚ¿¬ÀûÀÎ ÆÄ¿­À» ¸»Çϴµ¥ µ¿Åë°ú ¹ß¿­À» ¼ö¹ÝÇÑ °ß°©°ñ¾È ȤÀº Èä°ñÇÏ µ¿ÅëÀ» È£¼ÒÇÏ°í ¼îÅ© »óŰ¡ ¹ß»ýÇϱ⵵ ÇÑ´Ù. ±¤¹üÀ§ÇÑ ±«»ç¼º Á¾°Ýµ¿¿°Àº ÆíÃø ȤÀº ¾çÃø¼º ³óÈäÀ» ÃÊ·¡½Ã۱⵵ ÇÏ¿© 24~48½Ã°£³» »ç¸Á½Ã۱⵵ ÇÑ´Ù. ÀÓ»ó Áõ»óÀº ÈäºÎ X-¼± »çÁø»ó °æºÎ Á¶Á÷¸é°ú Á¾°Ýµ¿³» °ø±â°¡ ³ªÅ¸³ª°í Á¾°Ýµ¿ »óÀÌ È®´ëµÇ°í Á¾°Ýµ¿¿¡ ¾×¸é»ó°ú µå¹°°Ô ½É³¶°ú ÅëÇØ ½É³¶³» ¾×¸é»óÀÌ º¸À̱⵵ ÇÑ´Ù. ½Äµµ Á¶¿µ¼úµµ Áø´ÜÀÌ °¡´ÉÇÏ¸é °¡´ÉÇÑ ÇÑ ºü¸¥ Áø´Ü°ú Ä¡·á¸¸ÀÌ È¯ÀÚÀÇ »ýÁ¸À²À» ³ôÀÏ ¼ö ÀÖ´Ù.
  • bottle mouse syndrome
    ¿ìÀ¯º´ ¿ì½Ä
    Àå½Ã°£ ¿ìÀ¯¸¦ ¹°°í ÀÖ´Â À¯¾Æ¿¡ È£¹ß, ÇÏ¾Ç ÀýÄ¡¿¡´Â ¿ì½ÄÁõÀÌ ¾ø´Ù.
  • brain death syndrome
    ³ú»ç ÁõÈıº
  • brain stem syndrome
    ³ú°£ ÁõÈıº
  • Briquets syndrome
    ºê¸®ÄÉ ÁõÈıº
    µ¿ÀǾî=ataxia syndrome. ºê¸®ÄÉ ¿îµ¿ ½ÇÁ¶ ÁõÈıº.
  • brittle hair syndrome
    Ãë¾à ¸ð¹ß ÁõÈıº
  • bronze baby syndrome
    ûµ¿»ö ¾Æ±â ÁõÈıº
  • bruising syndrome
    Ÿ¹Ú»ó ÁõÈıº
  • burning feel syndrome
    ÀÛ¿­°¨ ÁõÈıº, ¼ÒÀÛÁ· ÁõÈıº
  • Bäfverstedt's syndrome
    º£Æä¸£½ºÅׯ® ÁõÈıº
  • capillary leak syndrome
    ¸ð¼¼Ç÷°ü ´©Ãâ ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
diabetes, type 2 Non-insulin dependent diabetes, adult-onset diabetes or insulin-resistant diabetes.
(12 Dec 1998)
disease, gaucher's type 1 A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
influenza type a A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection.
Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine.
(27 Sep 1997)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon type II <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
ocean-type fish An anadromous fish that shows no indication on its scales or other hard parts of an extended freshwater residence early in its life.
(09 Oct 1997)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 1 nephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 2 glomerulonephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
Ellis type 2 nephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
Ellis type II <nephrology> A type of nephritis that is characterised by low serum albumin, large amount of protein in the urine and swelling (oedema). Swelling, weight gain, high blood pressure and anorexia are key features. Nephrotic syndrome can be seen with a number of illness that cause damage to the kidney glomerulus.
Examples include diabetes, hereditary disorders, lupus, multiple myeloma, amyloidosis, glomerulonephritis, minimal change disease and membranous glomerulonephritis.
(27 Sep 1997)
erotomanic type of paranoid disorder The false belief that one is loved by another such as a movie star or a casual acquaintance.
(05 Mar 2000)
tuberculin-type hypersensitivity A local or generalised response that begins 24 to 48 hours after exposure to an antigen.
See: cell-mediated reaction.
Synonym: contact hypersensitivity, delayed hypersensitivity, late reaction, tuberculin-type hypersensitivity.
(05 Mar 2000)
jealous type of paranoid disorder The false belief that one's spouse or lover is unfaithful and leading to repeated confrontation, or the taking of extraordinary steps to intervene in the imagined infidelity.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á